A Cross-Trial Comparison of Pegcetacoplan and Avacincaptad Pegol by Paul Hahn, M.D.

Published Date: 10 Aug 2023

In patients with geographic atrophy, Dr. Dot Hahn discusses an indirect comparison that is anchored matching-adjusted and suggests that monthly pegcetacoplan is more effective than avacincaptad pegol at reducing observed lesion growth.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Charles III, King of Kings, is Cancerous.

2.

Chemo-Free Quadruplet Shows Promise as DLBCL's First Therapy.

3.

Perioperative Anti-PD-1 in Soft-Tissue Sarcoma Boosts Disease-Free Survival

4.

Merck enhances its oncology pipeline by means of a strategic alliance with Hengrui.

5.

WHO releases new R&D landscape analyses highlighting gaps and inequities in cancer research


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot